-

 HITLAB Validates MedsEngine’s Value in Treating Chronic Diseases

NEW YORK--(BUSINESS WIRE)--HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis using the Nielsen heuristic framework, comprehensive review of the peer-reviewed evidence, and economic value analysis.

HITLAB Validates MedsEngine's Value in Chronic Disease Control

Share

HITLAB Chairman, Stan Kachnowski stated, “MedsEngine is among the most clinically rigorous and outcomes-validated decision support platforms HITLAB has evaluated. In a landscape crowded with digital health promises, MedsEngine delivers something rare: a decade of real-world evidence that durably moves the needle on chronic disease control at scale.”

The four disease modules that MedsEngine supports impact over 60% of the adult population and represent nearly 64% of chronic disease cost. Dr. Doug Romer, MedsEngine CMO, stated, “HITLAB’s findings identify the improved outcomes and cost benefits derived from using MedsEngine to treat chronic diseases. Users achieved US leading hypertension control for over 90% of patients in less than 2 office visits. Clinicians can provide guideline directed treatment for type 2 diabetes and cholesterol management in a matter of seconds.”

MedsEngine uses secure FHIR-based interoperability with EHR’s to turn patient-specific data already available in the EHR into guideline-directed recommendations within the clinician’s workflow, reducing manual review and improving office efficiency.

For more information about MedsEngine or to view the full HITLAB report visit www.medsengine.com or contact us at hello@medsengine.com

About MedsEngine

MedsEngine develops EHR-integrated clinical decision support applications that generate real-time, personalized, evidence-based medication recommendations for hypertension, cholesterol management, type 2 diabetes, and heart failure. Medical groups utilizing MedsEngine have seen nation-leading hypertension control, higher HEDIS scores and Star ratings, lower medical costs, standardized care across all providers, improved office workflow and greater patient understanding and satisfaction.

Contacts

hello@medsengine.com

Industry:

MedsEngine

Release Versions
English

Contacts

hello@medsengine.com

More News From MedsEngine

MedsEngine Helps Medical Practices Unlock $30,000 Per Provider in Additional Annual Revenue

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a leader in chronic disease management software, announced today that medical practices using its Cholesterol and Type 2 Diabetes modules could generate up to $30,000 in additional annual revenue. This estimate is based on a typical patient panel of 2,000 and leverages national averages and published financial data related to these chronic conditions. “Using MedsEngine is a win-win for providers and patients,” said Dr. Doug Romer, Chief Medical Officer...

MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits. These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024...

MedsEngine Achieves SOC 2 Type II Certification: Reinforcing Our Commitment to Data Security

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a provider of chronic disease management software, is proud to announce that it has successfully attained SOC 2 Type II certification. This certification, awarded by the American Institute of Certified Public Accountants (AICPA), is a rigorous audit that evaluates a company's controls relevant to security, availability, processing integrity, confidentiality, and privacy. Dr. Doug Romer, CMO, stated, “this milestone underscores MedsEngine’s continued co...
Back to Newsroom